REGiMMUNE raises $4,200,000

REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised $4.2 million U.S. in a Series B venture capital financing REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders